833-PET-HERO(833-738-4376)
Image: PetCure Oncology

Clinical Trials and Research: How PetCure Oncology is Advancing Cancer Care for Pets

PetCure Oncology is on a mission to revolutionize pet cancer care with stereotactic radiation (SRS/SRT), an advanced form of radiation therapy that has been proven effective in humans. To date, we’ve seen SRS/SRT treat many different types of pet cancers in more than 2,500 patients—and our specialists are determined to understand the safety and benefits of SRS/SRT on all tumors.

 

Whether you’re a pet parent or veterinarian, you may be able to take part in a clinical trial we’re currently conducting. Please see below for more information.

Osteosarcoma Trial

PetCure Oncology, in collaboration with Varian Medical Systems, is currently accepting patients into a clinical trial to evaluate dogs that receive stereotactic radiation (SRS/SRT) to treat osteosarcoma of the appendicular skeleton. Osteosarcoma is the most commonly occurring form of bone cancer.

While amputation has long been considered the most effective form of local tumor control for osteosarcoma of a limb, early data collected by PetCure Oncology suggests that SRS/SRT may provide a longer median survival time. The purpose of this trial is to analyze whether SRS/SRT increases the circulation of immune cells that are responsible for attacking cancer.

Enrollment in this trial is for dogs undergoing SRS/SRT for treatment of qualified cases of osteosarcoma. It involves participation in seven (7) scheduled blood draws and two (2) x-rays, beginning pre-treatment and extending 12-months following treatment. All trial-related blood draws and x-rays will be free of charge, and pet owners can receive up to $1,000 in compensation.

 

If you are the owner or veterinarian of a dog with diagnosed or suspected osteosarcoma, contact ClinicalTrials@PetCureOncology.com or call 833-PET-HERO for additional details.

Lung Tumor Trial

PetCure Oncology is currently accepting patients into a clinical trial to evaluate stereotactic radiation (SRS/SRT) in the treatment of primary lung tumors in dogs.

Prior to the emergence of SRS/SRT, surgery was the primary treatment option for dogs diagnosed with lung tumors. But SRS/SRT has changed the way we approach cancer care for pets, offering non-surgical therapy with unprecedented precision that, in many cases, enables the treatment of tumors previously considered “untreatable.” If your pet has been diagnosed with a lung tumor, there may be hope. SRS/SRT has become the standard of care in the treatment of lung tumors in humans. This study is intended to prove the hypothesis that dogs can also be safely and effectively treated for lung tumors with SRS/SRT.

If your dog has been diagnosed with a primary lung tumor, or if you are a veterinarian with a canine patient that has been diagnosed with one, they may be eligible for subsidized SRS/SRT treatment through this clinical trial.

PET OWNERS    VETERINARIANS

BACK TO TOP